Baker Avenue Asset Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $21.5M | Sell |
85,535
-23,848
| -22% | -$5.13M | 0.41% | 58 |
|
|
2026
Q1 | $23.8M | Buy |
109,383
+24
| +0% | +$5.32K | 0.54% | 45 |
|
|
2025
Q4 | $25M | Sell |
109,359
-328
| -0.3% | -$74.7K | 0.58% | 43 |
|
|
2025
Q3 | $25.4M | Buy |
109,687
+4,305
| +4% | +$877K | 0.61% | 38 |
|
|
2025
Q2 | $19.6M | Sell |
105,382
-440
| -0.4% | -$81.8K | 0.56% | 49 |
|
|
2025
Q1 | $22.2M | Buy |
105,822
+223
| +0.2% | +$43.4K | 0.69% | 31 |
|
|
2024
Q4 | $18.8M | Sell |
105,599
-4,565
| -4% | -$839K | 0.57% | 41 |
|
|
2024
Q3 | $21.8M | Buy |
110,164
+8,878
| +9% | +$1.66M | 0.69% | 29 |
|
|
2024
Q2 | $17.4M | Buy |
101,286
+10,021
| +11% | +$1.66M | 0.59% | 41 |
|
|
2024
Q1 | $16.6M | Buy |
91,265
+1,247
| +1% | +$215K | 0.65% | 43 |
|
|
2023
Q4 | $14M | Buy |
90,018
+7,091
| +9% | +$1.03M | 0.61% | 46 |
|
|
2023
Q3 | $12.4M | Buy |
82,927
+2,616
| +3% | +$384K | 0.62% | 42 |
|
|
2023
Q2 | $10.8M | Buy |
80,311
+9,242
| +13% | +$1.36M | 0.54% | 50 |
|
|
2023
Q1 | $11.3M | Sell |
71,069
-43,623
| -38% | -$6.67M | 0.61% | 46 |
|
|
2022
Q4 | $18.5M | Sell |
114,692
-5,059
| -4% | -$776K | 1.11% | 25 |
|
|
2022
Q3 | $16.1M | Buy |
119,751
+8,977
| +8% | +$1.29M | 1.01% | 25 |
|
|
2022
Q2 | $17M | Sell |
110,774
-100,612
| -48% | -$15.4M | 1.12% | 25 |
|
|
2022
Q1 | $34.3M | Sell |
211,386
-43,688
| -17% | -$6.35M | 1.75% | 12 |
|
|
2021
Q4 | $34.5M | Buy |
255,074
+23,113
| +10% | +$2.73M | 1.73% | 11 |
|
|
2021
Q3 | $25M | Buy |
231,961
+8,171
| +4% | +$934K | 1.43% | 18 |
|
|
2021
Q2 | $25.2M | Buy |
223,790
+13,073
| +6% | +$1.47M | 1.43% | 18 |
|
|
2021
Q1 | $22.8M | Buy |
210,717
+4,571
| +2% | +$489K | 1.4% | 21 |
|
|
2020
Q4 | $22.1M | Buy |
206,146
+28,059
| +16% | +$2.7M | 1.5% | 18 |
|
|
2020
Q3 | $15.6M | Buy |
178,087
+9,209
| +5% | +$867K | 1.2% | 28 |
|
|
2020
Q2 | $16.6M | Buy |
168,878
+93,926
| +125% | +$8.27M | 1.37% | 24 |
|
|
2020
Q1 | $5.71M | Sell |
74,952
-29,974
| -29% | -$2.55M | 0.68% | 26 |
|
|
2019
Q4 | $9.29M | Sell |
104,926
-3,527
| -3% | -$293K | 0.67% | 37 |
|
|
2019
Q3 | $8.21M | Buy |
108,453
+23,739
| +28% | +$1.63M | 0.65% | 37 |
|
|
2019
Q2 | $6.16M | Buy |
84,714
+68,298
| +416% | +$5.37M | 0.5% | 55 |
|
|
2019
Q1 | $1.32M | Sell |
16,416
-14,418
| -47% | -$1.18M | 0.11% | 116 |
|
|
2018
Q4 | $2.84M | Buy |
30,834
+2,099
| +7% | +$185K | 0.28% | 77 |
|
|
2018
Q3 | $2.72M | Sell |
28,735
-8,330
| -22% | -$790K | 0.22% | 88 |
|
|
2018
Q2 | $3.43M | Buy |
37,065
+3,248
| +10% | +$317K | 0.3% | 78 |
|
|
2018
Q1 | $3.2M | Buy |
33,817
+6,641
| +24% | +$730K | 0.29% | 76 |
|
|
2017
Q4 | $2.63M | Buy |
27,176
+9,346
| +52% | +$881K | 0.25% | 83 |
|
|
2017
Q3 | $1.58M | Buy |
17,830
+1,822
| +11% | +$139K | 0.18% | 90 |
|
|
2017
Q2 | $1.16M | Buy |
16,008
+12,535
| +361% | +$843K | 0.15% | 87 |
|
|
2017
Q1 | $226K | Sell |
3,473
-166
| -5% | -$10.4K | 0.03% | 185 |
|
|
2016
Q4 | $228K | Sell |
3,639
-65
| -2% | -$3.97K | 0.03% | 189 |
|
|
2016
Q3 | $234K | Buy |
+3,704
| New | +$240K | 0.03% | 179 |
|
|
2015
Q4 | – | Sell |
-5,073
| Closed | -$276K | – | 179 |
|
|
2015
Q3 | $276K | Sell |
5,073
-66,834
| -93% | -$4.35M | 0.05% | 162 |
|
|
2015
Q2 | $4.83M | Buy |
71,907
+24,433
| +51% | +$1.6M | 0.64% | 38 |
|
|
2015
Q1 | $2.78M | Sell |
47,474
-32,512
| -41% | -$1.96M | 0.37% | 86 |
|
|
2014
Q4 | $5.23M | Sell |
79,986
-5,555
| -6% | -$350K | 0.73% | 30 |
|
|
2014
Q3 | $4.94M | Buy |
85,541
+6,883
| +9% | +$382K | 0.69% | 27 |
|
|
2014
Q2 | $4.44M | Buy |
78,658
+3,876
| +5% | +$203K | 0.64% | 33 |
|
|
2014
Q1 | $3.84M | Buy |
74,782
+69,782
| +1,396% | +$3.53M | 0.65% | 40 |
|
|
2013
Q4 | $264K | Buy |
+5,000
| New | +$246K | 0.05% | 192 |
|
Other funds holding ABBV
ECSS
ATO
Baker Avenue Asset Management's ABBV Position: Q2 2026 in Review
Baker Avenue Asset Management reduced its AbbVie (ABBV) stake by 22% in Q2 2026, selling an estimated $5.13M and leaving 85,535 shares worth $21.5M. The position accounts for 0.41% of the portfolio, ranked #58.
Baker Avenue Asset Management first reported a position in ABBV in Q4 2013 and has held it in 48 quarters since. The position peaked at $34.5M in Q4 2021. 2,010 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Baker Avenue Asset Management held 85,535 shares of AbbVie worth $21.5M as of Q2 2026.
- Baker Avenue Asset Management sold 23,848 AbbVie shares in Q2 2026, an estimated $5.13M.
- AbbVie made up 0.41% of Baker Avenue Asset Management's portfolio in Q2 2026, its #58 holding.
- Baker Avenue Asset Management first reported a position in AbbVie in Q4 2013 and has held it in 48 quarters since.
- Baker Avenue Asset Management's AbbVie position peaked at $34.5M in Q4 2021.
- 2,010 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Baker Avenue Asset Management's 13F filing for Q2 2026, filed 28 Jul 2026.